A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth.

The goal of our study was to raise monoclonal antibodies (mAbs) against endothelial cell-surface proteins specific for tumor vasculature. Here, we describe the generation and intensive characterization of mAb AA98, including its functional properties and its antigen identification. In our study, an enhanced mAb AA98 immunoreactivity was observed on stimulated human umbilical vein endothelial cells (HUVECs). In addition, mAb AA98 showed remarkably restricted immunoreactivity against intratumoral neovasculature compared with blood vessels of normal tissues. We identified the AA98 antigen as human CD146, an adhesion molecule belonging to the immunoglobulin superfamily. Data from in vitro experiments imply structural and signaling functions for endothelial CD146; however, the role of CD146 in vivo is largely unknown. Here, we show that mAb AA98 displays antiangiogenic properties in vitro and in vivo. Proliferation and migration of HUVECs were inhibited by mAb AA98 as was angiogenesis in chicken chorioallantoic membrane (CAM) assays and tumor growth in 3 xenografted human tumor models in mice. Our data provide new insights into the function of CD146 on endothelial cells, validate CD146 as a novel target for antiangiogenic agents, and demonstrate that mAb AA98 has potential as a diagnostic and therapeutic agent in vascular and cancer biology.

[1]  E. Heyderman,et al.  An improved Iodogen method of labelling antibodies with 123I , 1986, Nuclear medicine communications.

[2]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[3]  W. Risau.  Differentiation of endothelium , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  A. Składanowski,et al.  Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. , 1993, Biochemical pharmacology.

[5]  A. Şeftalioğlu,et al.  Expression of CD146 adhesion molecules (MUC18 or MCAM) in the thymic microenvironment. , 2000, Acta histochemica.

[6]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[7]  Origin of endothelial progenitors in human postnatal bone marrow , 2002 .

[8]  D. Elder,et al.  Isolation and functional characterization of the A32 melanoma-associated antigen. , 1994, Cancer research.

[9]  C. Verfaillie,et al.  Origin of endothelial progenitors in human postnatal bone marrow. , 2002, The Journal of clinical investigation.

[10]  J. Kinsella,et al.  Induction of endothelial cell differentiation in vitro by fibroblast-derived soluble factors. , 1994, Experimental cell research.

[11]  Suyun Huang,et al.  Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. , 2002, Cancer research.

[12]  É. Vivier,et al.  Outside-in Signaling Pathway Linked to CD146 Engagement in Human Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[13]  I. Shih,et al.  Expression of Mel-CAM in implantation site intermediate trophoblastic cell line, IST-1, limits its migration on uterine smooth muscle cells. , 1998, Journal of cell science.

[14]  M. Lampugnani,et al.  Interendothelial junctions: structure, signalling and functional roles. , 1997, Current opinion in cell biology.

[15]  R. Hebbel,et al.  Origins of circulating endothelial cells and endothelial outgrowth from blood. , 2000, The Journal of clinical investigation.

[16]  E. Wayner,et al.  Circulating activated endothelial cells in sickle cell anemia. , 1997, The New England journal of medicine.

[17]  N. Bander,et al.  Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.

[18]  A. Le Bivic,et al.  Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. , 2001, Blood.

[19]  G. Groenewegen,et al.  CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells. , 1997, Blood.

[20]  J. Palazzo,et al.  The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. , 1997, The American journal of pathology.

[21]  J. Lehmann,et al.  MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[23]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[24]  I. Shih,et al.  Expression of melanoma cell adhesion molecule in intermediate trophoblast. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[25]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[26]  I. Shih,et al.  A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[27]  K. Kirsch,et al.  Genomic organization of the melanoma-associated glycoprotein MUC18: implications for the evolution of the immunoglobulin domains. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Peter Carmeliet,et al.  Molecular mechanisms of lymphangiogenesis in health and disease. , 2002, Cancer cell.

[29]  S. Rafii,et al.  Circulating endothelial precursors: mystery, reality, and promise. , 2000, The Journal of clinical investigation.

[30]  M. Schwartz,et al.  Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. , 2001, Journal of cell science.

[31]  T. Roberts,et al.  Cell Density Modulates Protein-tyrosine Phosphorylation* , 1998, The Journal of Biological Chemistry.

[32]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[33]  É. Vivier,et al.  Activation of Human Endothelial Cells via S-Endo-1 Antigen (CD146) Stimulates the Tyrosine Phosphorylation of Focal Adhesion Kinase p125FAK * , 1998, The Journal of Biological Chemistry.

[34]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[35]  B. Gumbiner,et al.  Cell Adhesion: The Molecular Basis of Tissue Architecture and Morphogenesis , 1996, Cell.

[36]  J. Enenstein,et al.  Identification and functional assessment of endothelial P1H12. , 2001, The Journal of laboratory and clinical medicine.

[37]  C. Fletcher,et al.  Expression of adhesion molecules on the endothelium of normal tissue vessels and vascular tumors. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[38]  M. Moses.  The Regulation of Neovascularization by Matrix Metalloproteinases and Their Inhibitors , 1997 .

[39]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[40]  A Vacca,et al.  The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. , 1996, The International journal of developmental biology.

[41]  H. Pehamberger,et al.  Influence of MUC18/MCAM/CD146 expression on human melanoma growth and metastasis in SCID mice , 1999, International journal of cancer.

[42]  J. Sampol,et al.  Identification of the S-Endo 1 endothelial-associated antigen. , 1996, Biochemical and biophysical research communications.

[43]  J. Guan,et al.  Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. , 1996, Journal of cell science.

[44]  M A Moses,et al.  The regulation of neovascularization of matrix metalloproteinases and their inhibitors. , 1998, Stem cells.

[45]  I. Zachary,et al.  Vascular Endothelial Growth Factor Stimulates Tyrosine Phosphorylation and Recruitment to New Focal Adhesions of Focal Adhesion Kinase and Paxillin in Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[46]  M. Herlyn,et al.  Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication , 2001, Oncogene.

[47]  M. Bar‐eli,et al.  Melanoma progression–associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand , 1997 .

[48]  E. Kyo.  Inhibition of 3H-TdR uptake for human gastric carcinoma cells by epidermal growth factor specific antibody. , 1991, Hiroshima journal of medical sciences.

[49]  G. Bazzoni,et al.  Divalent Cations and Ligands Induce Conformational Changes That Are Highly Divergent among β1 Integrins* , 1998, The Journal of Biological Chemistry.

[50]  I. Shih,et al.  Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion. , 1997, Cancer research.

[51]  J. Johnson,et al.  Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. , 1997, Cancer research.

[52]  D. Vestweber,et al.  A monoclonal antibody against an activation epitope on mouse integrin chain beta 1 blocks adhesion of lymphocytes to the endothelial integrin alpha 6 beta 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[53]  I. Shih.  The role of CD146 (Mel‐CAM) in biology and pathology , 1999, The Journal of pathology.

[54]  J. Konopa.  G2 block induced by DNA crosslinking agents and its possible consequences. , 1988, Biochemical pharmacology.

[55]  D. Hicklin,et al.  Monoclonal antibody strategies to block angiogenesis. , 2001, Drug discovery today.

[56]  M. Lampugnani,et al.  Endothelial adhesion molecules in the development of the vascular tree: the garden of forking paths. , 1999, Current opinion in cell biology.

[57]  J. Johnson,et al.  MUC18/MCAM (CD146), an activation antigen of human T lymphocytes. , 1997, Journal of immunology.